25 studies found for:    AMG479
Show Display Options
Rank Status Study
21 Active, not recruiting Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer
Condition: Ovarian Neoplasms
Interventions: Drug: AMG 479;   Drug: AMG 479 Placebo
22 Completed AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin Lymphoma
Conditions: Lymphoma;   Prostate Cancer;   Sarcoma;   Small Intestine Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Biological: ganitumab;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: biopsy
23 Withdrawn Combination Chemotherapy With or Without Ganitumab in Treating Patients With Previously Untreated Metastatic Pancreatic Cancer
Condition: Pancreatic Cancer
Interventions: Biological: ganitumab;   Drug: fluorouracil;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium;   Drug: oxaliplatin;   Other: placebo;   Other: questionnaire administration
24 Completed Ph2 Biomarker (Mechanism of K-ras Dependency) in Wt KRAS Metastatic Colorectal Cancer Patients
Condition: Metastatic Colorectal Cancer
Interventions: Drug: Panitumumab;   Drug: AMG 479;   Drug: Irinotecan
25 Recruiting I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Conditions: Breast Neoplasms;   Breast Cancer;   Breast Tumors
Interventions: Drug: Standard Therapy;   Drug: AMG 386;   Drug: AMG 479 (Ganitumab) plus Metformin;   Drug: MK-2206 with or without Trastuzumab;   Drug: AMG 386 and Trastuzumab;   Drug: T-DM1 and Pertuzumab;   Drug: Pertuzumab and Trastuzumab;   Drug: Ganetespib

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-25) Next Page   
Indicates status has not been verified in more than two years